Welcome to Shanghai Probechem Biochemicals Co Ltd !Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : Debio 0932
CAS No.: 1061318-81-7
Catalog No.: PC-49868Not For Human Use, Lab Use Only.
Debio 0932 (CUDC-305, RGRN-305) is a highly potent, oral and BBB-penetrant HSP90 inhibitor, shows high affinity for HSP90alpha/beta and HSP90 complex derived from cancer cells with IC50 of 100 nM and 48.8 nM, respectively.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 5 mg | $128 | In stock | |
| 10 mg | $188 | In stock | |
| 25 mg | $278 | In stock | |
| 50 mg | $478 | In stock | |
| 100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Debio 0932 (CUDC-305, RGRN-305) is a highly potent, oral and BBB-penetrant HSP90 inhibitor, shows high affinity for HSP90alpha/beta and HSP90 complex derived from cancer cells with IC50 of 100 nM and 48.8 nM, respectively.
Debio 0932 (CUDC-305) displays potent antiproliferative activity against a broad range of cancer cell lines with mean IC50 of 220 nM.
Debio 0932 (CUDC-305) exhibits dose-dependent antitumor activity in an s.c. xenograft model of U87MG glioblastoma and significantly prolongs animal survival in U87MG orthotopic model.
Debio 0932 (CUDC-305) also displays potent antitumor activity in animal models of erlotinib-resistant non-small cell lung cancer and induces tumor regression in animal models of MDA-MB-468 breast cancer and MV4-11 acute myelogenous leukemia.
Debio 0932 (CUDC-305) binds strongly to HSP90 extracted from erlotinib-resistant NSCLC cells (IC50=70 nM).
Debio 0932 (CUDC-305) potently inhibits tumor growth in subcutaneous xenograft models of H1975 and A549, which harbor EGFR T790M mutation or K-ras mutations conferring acquired and primary erlotinib resistance, respectively.
| M.Wt | 442.58 | |
| Formula | C22H30N6O2S | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
2-((6-(dimethylamino)benzo[d][1,3]dioxol-5-yl)thio)-1-(2-(neopentylamino)ethyl)-1H-imidazo[4,5-c]pyridin-4-amine |
|
1. Bao R, et al. Clin Cancer Res. 2009 Jun 15;15(12):4046-57.
2. Bao R, et al. Mol Cancer Ther. 2009 Dec;8(12):3296-306.
3. Isambert N, et al. Ann Oncol. 2015 May;26(5):1005-1011.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
